Relmada Therapeutics (RLMD)

Earnings in 2026 (TTM): -€50.35 Million

According to Relmada Therapeutics's latest financial reports the company's current earnings are N/A. In 2025 the company made an earning of -€50.42 Million, an increase over its 2024 earnings that were of -€70.27 Million. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.

Earnings history for Relmada Therapeutics from 2012 to 2026

Annual earnings

Year	Earnings	Change
2026 (TTM)	-€50.35 Million	-0.15%
2025	-€50.42 Million	-28.25%
2024	-€70.27 Million	-19.04%
2023	-€86.8 Million	-37.09%
2022	-€0.14 Billion	24.88%
2021	-€0.12 Billion	111.5%
2020	-€52.24 Million	296.24%
2019	-€13.19 Million	-12.05%
2018	-€14.99 Million	183.21%
2017	-€5.3 Million	-23.25%
2016	-€6.9 Million	-235.74%
2015	€5.08 M
2013	-€0.05 Million	144.12%
2012	-€0.02 Million

Earnings for similar companies or competitors

Company	Earnings	Earnings differencediff.	Country
Cytokinetics CYTK	-€0.73 Billion	1,309.04%	🇺🇸 USA
Taro Pharmaceutical TARO	€38.41 M	-174.27%	🇮🇱 Israel

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Earnings for Relmada Therapeutics (RLMD)

Earnings in 2026 (TTM): -€50.35 Million